The Global Transdermal Patch Market is Expected to Reach $20 Billion by 2028 –

DUBLIN-March 16, 2022 – Transdermal patches have been developed as a result of technological breakthroughs in medicine delivery. The active elements of medications are delivered across skin into the systemic blood circulation in a continuous or measured way through diffusion by transdermal skin patches. Transdermal patches have other benefits besides being easy for patients and non-invasive, such as avoiding first-pass digestion and gastric/enzymatic degradation. Transdermal patches are currently being marketed as easy-to-use, convenient, and long-lasting goods. Depending on the therapeutic indication, these patches can be worn for up to seven days.

The positive reception of transdermal patches on the global market has fueled more research and development in this field. In 2019, the US Food and Drug Administration approved Secuado, the first transdermal patch to treat Schizophrenia. In addition, Gedeon Richter UK announced in 2021 that it has been designated as the marketing authorization holder (MAH) for Evra, once-weekly contraception for women of reproductive age and the UK’s only transdermal contraceptive patch. The increasing number of product launches in the global industry will boost the market growth.

The global transdermal patch pipeline is full, indicating a bright future for these patches in the next years. For example, in a non-GLP rabbit pharmacokinetic (PK) and skin irritation research, Starton Therapeutics’ STAR-LLD continuous-delivery transdermal patch containing lenalidomide demonstrated encouraging results. Furthermore, the US FDA has set a March 11, 2022 deadline for the new drug application for Aldarity (donepezil transdermal system) for the treatment of individuals with dementia caused by mild, moderate, or severe Alzheimer’s disease. Aldarity is a donepezil transdermal formulation designed to be used once a week for seven days with continuous adherence. During the forecast period, these developing trends will force the market forward.

Nicoderm. Image from Wikipedia
Nicoderm. Image from Wikipedia

Currently, there is no transdermal patch in the vaccination category, indicating that there are many unexplored prospects for pharmaceutical businesses in this field. Several clinical trials are under underway to evaluate new vaccination patches for influenza, HIV, COVID-19, and other diseases. Institut Pasteur Korea (IPK) has signed a research service agreement with Juvic Inc. for the cooperative development of microneedle-based influenza vaccines in the year 2022. This collaboration is expected to speed up the development of a microneedle influenza vaccination patch by combining Juvic’s microneedle production technology with IPK’s vaccine research and development skills. Notably, the microneedle-based vaccine not only significantly lowers pain during immunization but can also be administered at room temperature.

The global transdermal patch market is expected to witness high growth rates which are due to the presence of key players and established healthcare infrastructure. Further beneficial government initiatives and an increase in the number of research partnerships are also expected to increase the market growth during the forecast period. Besides, the high adoption rate of advanced technologies is also expected to impel the growth of the market in the region. As per our report findings, the global transdermal patch market is expected to surpass US$ 20 Billion by 2028.

Research and Markets
Research and Markets

Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028 Report Highlights:

  • Research Methodology
  • Global & Regional Transdermal Path Market Outlook
  • Global Transdermal Patch Market Opportunity > USD 20 Billion
  • Clinical Trials Insight By Company, Indication, Drug Molecule & Phase
  • Comprehensive Insight On 60 Transdermal Patch Available Commercially
  • Comprehensive Insight On 80 Transdermal Patch In Clinical Trials By Phase
  • Transdermal Patch Dosage & Price Availability By Indication
  • Competitive Landscape

Key Topics Covered:

1. Introduction to Transdermal Patch

2. Transdermal Patches Classification

3. Mechanism of Transdermal Patch Drug Delivery

4. Global Transdermal Patch Market Outlook

5. Global Transdermal Patch Market Trends by Region

6. Transdermal Patches for Cardiovascular Diseases – Market Availability, Dosage & Price Analysis

7. Opioid Drug Containing Transdermal Patches – Market Availability, Dosage & Price Analysis

8. Transdermal Patch in Hormonal Therapy – Market Availability, Dosage & Price Analysis

9. Transdermal Patches for Neurological Disorders – Market Availability, Dosage & Price Analysis

10. Transdermal Patches for Other Conditions – Market Availability, Dosage & Price Analysis

11. Global Transdermal Patch Clinical Pipeline Overview

12. Global Patch Clinical Pipeline By Company, Indication & Phase

13. Marketed Transdermal Patch Clinical Insight

14. Global Transdermal Patch Market Dynamics

15. Global Transdermal Patch Market Future Outlook 2028

16. Competitive Landscape

16.1 3M Pharmaceuticals

16.2 Acrux

16.3 Agile Therapeutics

16.4 Allergan

16.5 ANI Pharmaceuticals

16.6 Antares Pharma

16.7 Bayer HealthCare Pharmaceuticals

16.8 Corium International

16.9 Chase Pharmaceuticals

16.10 DURECT Corporation

16.11 Endo Pharmaceuticals

16.12 Fempharm

16.13 Hisamitsu Pharmaceutical

16.14 Immune Pharmaceuticals

16.15 Imprimis Pharmaceuticals

16.16 Ipsen Bioscience

16.17 Johnson & Johnson

16.18 LaSalle Laboratories

16.19 Lavipharm-increase

16.20 Luye Pharma

16.21 MINRAD International

16.22 NeurogesX

16.23 Noven Pharmaceuticals

16.24 NuPathe

16.25 Nuvo Research

16.26 Novartis

16.27 Pain Therapeutics

16.28 ProStrakan

16.29 Purdue Pharma

16.30 Sanofi

16.31 Scilex Pharmaceuticals

16.32 Senju Pharmaceutical

16.33 Somerset Pharmaceuticals

16.34 Teikoku Seiyaku

16.35 Therapeutic Discovery Corporation

16.36 Transdermal Delivery Solutions Corp

16.37 UCB

16.38 Xel Pharmaceuticals

16.39 Zosano Pharma

For more information about this report visit